PT2717914T - Formulações de libertação sustentada para administração de proteínas ao olho e métodos de preparação das mesmas - Google Patents

Formulações de libertação sustentada para administração de proteínas ao olho e métodos de preparação das mesmas

Info

Publication number
PT2717914T
PT2717914T PT128296555T PT12829655T PT2717914T PT 2717914 T PT2717914 T PT 2717914T PT 128296555 T PT128296555 T PT 128296555T PT 12829655 T PT12829655 T PT 12829655T PT 2717914 T PT2717914 T PT 2717914T
Authority
PT
Portugal
Prior art keywords
proteins
eye
delivery
methods
sustained release
Prior art date
Application number
PT128296555T
Other languages
English (en)
Inventor
Wong Vernon
Wood Louis
Huang Glenn
Original Assignee
Ramscor Inc
Icon Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor Inc, Icon Bioscience Inc filed Critical Ramscor Inc
Publication of PT2717914T publication Critical patent/PT2717914T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT128296555T 2011-06-10 2012-06-11 Formulações de libertação sustentada para administração de proteínas ao olho e métodos de preparação das mesmas PT2717914T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10

Publications (1)

Publication Number Publication Date
PT2717914T true PT2717914T (pt) 2019-12-18

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128296555T PT2717914T (pt) 2011-06-10 2012-06-11 Formulações de libertação sustentada para administração de proteínas ao olho e métodos de preparação das mesmas

Country Status (21)

Country Link
US (1) US9814773B2 (pt)
EP (1) EP2717914B1 (pt)
JP (1) JP6339011B2 (pt)
KR (1) KR20140060274A (pt)
CN (1) CN103945865B (pt)
AU (1) AU2012304909B2 (pt)
BR (1) BR112013031685B1 (pt)
CA (1) CA2838289C (pt)
CY (1) CY1122771T1 (pt)
DK (1) DK2717914T3 (pt)
ES (1) ES2761340T3 (pt)
HR (1) HRP20192276T1 (pt)
HU (1) HUE047737T2 (pt)
IN (1) IN2013MN02384A (pt)
LT (1) LT2717914T (pt)
MX (1) MX359119B (pt)
PL (1) PL2717914T3 (pt)
PT (1) PT2717914T (pt)
RS (1) RS60051B1 (pt)
SI (1) SI2717914T1 (pt)
WO (1) WO2013036309A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6530744B2 (ja) * 2013-05-24 2019-06-12 アイコン バイオサイエンス インコーポレイテッド 白内障手術後の炎症における徐放性デキサメタゾンの使用
WO2015169944A1 (en) * 2014-05-08 2015-11-12 Panoptes Pharma Ges.M.B.H. Compounds for treating ophthalmic diseases and disorders
EP3272362B1 (en) 2015-03-18 2023-12-13 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
AR105215A1 (es) * 2015-07-01 2017-09-13 Santen Pharmaceutical Co Ltd Formulación de depósito que contiene ésteres de ácido cítrico
MX2018001499A (es) * 2015-08-03 2018-08-01 Tolmar International Ltd Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
CN116942677A (zh) 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
JP7394770B2 (ja) 2018-02-09 2023-12-08 アイコン バイオサイエンス,インコーポレイテッド 注射器から少量の用量を装填および送達するためのシステム、キット、および方法
EP3787609A4 (en) 2018-05-01 2022-01-05 Chibi, Inc. EYE DROP FORMULATION AND PROLONGED METHOD OF DRUG ADMINISTRATION TO THE RETINAL
WO2019213330A1 (en) 2018-05-01 2019-11-07 Idrop, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
US20230190657A1 (en) * 2020-05-22 2023-06-22 Trustees Of Boston University Methods and compositions for treating a fibrotic disease
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
AU2022308198A1 (en) 2021-07-06 2024-02-01 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
CA2413157A1 (en) * 2000-06-28 2002-01-03 Atul J. Shukla Biodegradable vehicles and delivery systems of biologically active substances
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
EP1643968A1 (en) * 2003-05-30 2006-04-12 ALZA Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
BRPI0516830A (pt) * 2004-10-01 2008-09-23 Ramscor Inc composições de droga de liberação sustentada convenientemente implantáveis
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
EP2269663B1 (en) * 2009-07-03 2018-03-07 Armbruster Biotechnology GmbH Bone graft and biocomposite

Also Published As

Publication number Publication date
EP2717914B1 (en) 2019-10-30
WO2013036309A2 (en) 2013-03-14
AU2012304909B2 (en) 2017-06-08
CA2838289C (en) 2019-09-10
CY1122771T1 (el) 2021-05-05
BR112013031685B1 (pt) 2021-04-06
NZ619707A (en) 2015-01-30
ES2761340T3 (es) 2020-05-19
AU2012304909A1 (en) 2013-12-19
LT2717914T (lt) 2020-03-25
CA2838289A1 (en) 2013-03-14
MX359119B (es) 2018-09-14
MX2013014461A (es) 2014-05-14
KR20140060274A (ko) 2014-05-19
CN103945865B (zh) 2016-10-26
WO2013036309A3 (en) 2013-05-10
CN103945865A (zh) 2014-07-23
JP6339011B2 (ja) 2018-06-06
EP2717914A4 (en) 2015-05-13
BR112013031685A2 (pt) 2017-02-07
JP2014516087A (ja) 2014-07-07
HUE047737T2 (hu) 2020-05-28
EP2717914A2 (en) 2014-04-16
US9814773B2 (en) 2017-11-14
SI2717914T1 (sl) 2020-07-31
DK2717914T3 (da) 2020-01-20
IN2013MN02384A (pt) 2015-06-12
PL2717914T3 (pl) 2020-05-18
RS60051B1 (sr) 2020-04-30
US20140140992A1 (en) 2014-05-22
HRP20192276T1 (hr) 2020-05-15

Similar Documents

Publication Publication Date Title
HRP20192276T1 (hr) Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
IL265707A (en) Pharmaceutical preparations containing human antibodies to pcsk9
HK1251983A1 (zh) 親脂性藥劑的改進的胃腸外製劑以及製備和使用其的方法
IL230855A0 (en) Cabazitaxel formulations and methods for their preparation
HK1199739A1 (en) Algal lipid compositions and methods of preparing and utilizing the same
EP2654726A4 (en) SOLID DISPERSION FORMULATIONS AND METHODS OF USE
HRP20180633T1 (hr) Postupak za pripremu i provedbu smjese goriva
EP2663288A4 (en) PROCESS FOR THE PREPARATION OF VESICLES AND FORMULATIONS PRODUCED THEREFROM
ZA201307518B (en) Composition and method for enhancing the physical stability of agricultural oilbased suspension formulations
PT2757878E (pt) Método para a preparação e aperfeiçoamento de ferraduras
IL231505B (en) Pharmaceutical preparation and method for its production
EP2780009A4 (en) METHODS AND COMPOSITIONS FOR ENHANCED IL-MEDICATION ADMINISTRATION AND EXTENDED DELIVERY FORMULATIONS
IL228519A (en) Preparation of 5,3-dioxohexanoate ester in two stages
GB201104925D0 (en) Trehalose lipids for use in microemulsion formulations and methods of application thereof
ZA201105598B (en) Prolonged release pharmaceutical composition comprising galantamine and method for the preparation thereof
PT3326648T (pt) Composições farmacêuticas que compreendem anticorpos humanos para pcsk9